Navigation Links
Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales

PRINCETON, N.J., Nov. 26 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) appointed Patrick T. Higgins as Executive Vice President, Marketing & Sales, responsible for coordinating the global product launch and marketing activities for Pharmasset's drug candidates. Mr. Higgins, who has served as a consultant to Pharmasset since 2006, was recently Vice President, Sales & Marketing, Virology at Hoffmann-LaRoche, Inc. His areas of expertise include hepatology, HIV and cytomegalovirus for transplant patients. Mr. Higgins was responsible for directing the development and implementation of marketing and sales plans for Roche's US hepatology franchise, including the global launch of Pegasys(R) and Copegus(R) for the treatment of chronic hepatitis C infection.

Mr. Higgins has over 25 years of pharmaceutical industry sales and marketing experience. Throughout his career, he has participated in a total of 13 product launches for antiviral, oncology, dermatologic and allergy indications. Prior to joining Roche, Mr. Higgins served in a variety of advertising, sales and marketing roles at Schering Corporation. He was instrumental in developing Schering's Oncology/Biotech group that launched Intron-A(R) (interferon alfa-2b) for the treatment of chronic hepatitis.

"I am delighted to join Pharmasset at this stage of its development," stated Mr. Higgins. "I see the same characteristics and potential in Pharmasset's science, drug candidates and people that I saw in both Roche and Schering prior to their successful product launches."

"Pharmasset intends to commercialize clevudine for the treatment of chronic hepatitis B infection," stated Schaefer Price, Pharmasset's President & CEO. "To accomplish this goal, we plan to capitalize on Patrick's extensive experience in the field of hepatology, his personal relationships with key opinion leaders and his proven ability to build successful marketing and sales organizations."

Mr. Higgins received his M.B.A. from Seton Hall University and his Bachelor of Arts from Villanova University.

About Pharmasset

Pharmasset is a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, being developed for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for product registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, being developed as an oral treatment for chronic HCV infection, is enrolling a 4- week Phase 1 clinical trial in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) through a strategic collaboration with Roche. Racivir, being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche. Intron-A(R) is a registered trademark of Schering Corporation.


Alan Roemer, Vice President

Investor Relations & Corporate Communications

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that our collaboration with Roche will not continue or will not be successful, the risk that the on-going or anticipated clinical trials for any one or more of our product candidates will not be successful or will not provide meaningful data and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmassets Underwriters Release Shares from Lock-Up
2. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
3. WorldHeart Appoints David Pellone Chief Financial Officer
4. Novo Nordisk Appoints New Leader of North American Business
5. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
6. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
7. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
8. Resonant Medical Appoints New Vice President of Global Sales
9. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
Post Your Comments:
(Date:11/26/2015)... ... ... Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, announces ... new Q-Suite 6 platform is based on the latest Java Enterprise standards. By conforming ... of software for many key components of the suite. Much of the suite runs ...
(Date:11/25/2015)... ... ... Finnleo, a leader in the traditional and far-infrared sauna industry, announced a ... , For traditional saunas, Finnleo is offering 20% off all Nordic ... uses only European Grade A Nordic White Spruce from sustainably grown trees. Because of ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... Jacksonville, FL (PRWEB) , ... November 25, 2015 ... ... treatment center, is encouraging people across the country to celebrate their sobriety and ... invites people to post “before and after” photos this Thanksgiving with the hashtag ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm ... appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto ... Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
Breaking Medicine Technology: